Drug Profile
Research programme: neurokinin 1 receptor antagonists - Merck and Co.
Alternative Names: Hydroisoindoline tachykinin receptor antagonists - Merck; Hydroisoindoline-based human neurokinin-1 receptor antagonists - Merck; L-760735; Tetrahydroindolizinone NK1 antagonists - MerckLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Isoindoles; Pyrroles
- Mechanism of Action Neurokinin 1 antagonists; Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting; CNS disorders; Major depressive disorder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting in United Kingdom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting in USA
- 01 Sep 2011 Preclinical development for Chemotherapy induced nausea and vomiting is ongoing in USA